Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
May 16, 2005
- NBI Reaffirms Sales Target of \100 Bil. for FY2005
May 16, 2005
- SUEVEY
May 16, 2005
- Shionogi to Focus on Pain and Metabolic Syndrome in Addition to Infections
May 16, 2005
- PMDA Announces Provisional Measures to Improve Clinical Trial Consultation
May 16, 2005
- Mitsubishi Chemical, Mitsubishi Pharma to Come under New Holding Company
May 16, 2005
- JASMO Announces FY2005 Plans of Action
May 16, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 16, 2005
- 5th Bio Business Competition Japan
May 16, 2005
- R&D NEWS IN BRIEF
May 16, 2005
- WEBSITE NEWS
May 16, 2005
- REGULATORY NEWS IN BRIEF
May 16, 2005
- AstraZeneca to Recommend 5 mg Starting Dose of Crestor to Asians: EU Label
May 16, 2005
- Business Results
May 16, 2005
- NEW PRODUCTS
May 16, 2005
- Daiichi: Ethical Drug Sales Up 2.4% to \311,844 Mil.
May 16, 2005
- BUSINESS NEWS IN BRIEF
May 16, 2005
- Largest Number of Consultations Requested by US Ventures: JETRO
May 16, 2005
- Towa Seeking Partnership to Build Marketing Route to Major Hospitals
May 16, 2005
- Wave of Buy-outs Unlikely in Japan: Mr Mikel of IMS Health
May 16, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…